David Lazar - Titan Pharmaceuticals Principal Officer
| TTNP Stock | USD 3.65 0.01 0.27% |
Insider
David Lazar is Principal Officer of Titan Pharmaceuticals
| Age | 33 |
| Phone | 650 244 4990 |
| Web | https://www.titanpharm.com |
David Lazar Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Lazar against Titan Pharmaceuticals stock is an integral part of due diligence when investing in Titan Pharmaceuticals. David Lazar insider activity provides valuable insight into whether Titan Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Titan Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Titan Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Lazar over a month ago Acquisition by David Lazar of 2100000 shares of Cyclacel Pharmaceuticals subject to Rule 16b-3 | ||
David Lazar over three months ago Disposition of 821818 shares by David Lazar of LQR House at 1300000.0 subject to Rule 16b-3 | ||
David Lazar over three months ago Insider Trading | ||
David Lazar over six months ago Disposition of 550000 shares by David Lazar of OpGen subject to Rule 16b-3 |
Titan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.7263) % which means that it has lost $1.7263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6899) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gerald Md | Foghorn Therapeutics | N/A | |
| Susan Kahlert | Senti Biosciences | N/A | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 41 | |
| Philip Lee | Senti Biosciences | 42 | |
| Julie Person | Third Harmonic Bio | 51 | |
| Boyan MD | Indaptus Therapeutics | 57 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
| Allan MD | Foghorn Therapeutics | 49 | |
| PharmD Bigora | Processa Pharmaceuticals | 65 | |
| Wilson Wong | Senti Biosciences | N/A | |
| Robert Floyd | Processa Pharmaceuticals | 68 | |
| Daniela Santiesteban | Salarius Pharmaceuticals | N/A | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Fanny Cavalie | Foghorn Therapeutics | 46 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 47 | |
| Christine MBA | SAB Biotherapeutics | 69 | |
| Robert Ho | Third Harmonic Bio | 49 | |
| Natalie Holles | Third Harmonic Bio | 52 | |
| Eric JD | Lixte Biotechnology Holdings | 46 | |
| CPA CPA | GeoVax Labs | 62 | |
Management Performance
| Return On Equity | -3.69 | ||||
| Return On Asset | -1.73 |
Titan Pharmaceuticals Leadership Team
Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Crowley, Senior Administration | ||
| Gim Seow, CEO Board | ||
| Joe Schrei, Executive Operations | ||
| Katherine BeebeDeVarney, COO President | ||
| Weei Chay, Chief Officer | ||
| Marc MD, Ex Director | ||
| David Lazar, Principal Officer | ||
| Jennifer Kiernan, Executive Coordinator | ||
| Brynner Chiam, Acting Officer | ||
| Mike Fritz, National Director |
Titan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.69 | ||||
| Return On Asset | -1.73 | ||||
| Current Valuation | (2.71 M) | ||||
| Shares Outstanding | 914.23 K | ||||
| Shares Owned By Insiders | 45.46 % | ||||
| Shares Owned By Institutions | 1.85 % | ||||
| Number Of Shares Shorted | 27.3 K | ||||
| Price To Earning | (3.60) X | ||||
| Price To Book | 1.06 X | ||||
| Price To Sales | 1,234 X |
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.